Cargando…
IMMU-01. THE ONCOLYTIC VIRUS DELTA-24-RGD IN COMBINATION WITH AN AGONISTIC CD40 MAB INDUCES A DURABLE AND SYNERGISTIC ANTI-TUMOR IMMUNE EFFECT IN DIPG PRECLINICAL MODELS
With a 2-year survival less than 20%, Diffuse Intrinsic Pontine Glioma (DIPG) is the principal cause of pediatric death. Despite recent advances in the current treatments, the outcome for children with DIPGs remains dismal. Since the approval of T-VEC for melanoma by the FDA, oncolytic adenoviruses...
Autores principales: | Labiano, Sara, Laspidea, Virginia, Garcia-Moure, Marc, Puigdelloses, Montserrat, Becher, Oren J, Gomez-Manzano, Candelaria, Fueyo, Juan, Patiño-Garcia, Ana, Alonso, Marta M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168238/ http://dx.doi.org/10.1093/neuonc/noab090.109 |
Ejemplares similares
-
IMMU-06. DELTA-24-RGD EXPRESSING POSITIVE IMMUNE MODULATORS SHOW ANTI-DIPG EFFECT AND INCREASE TUMOR IMMUNE INFILTRATION
por: Laspidea, Virginia, et al.
Publicado: (2021) -
IMMU-18. Targeting Antigen Presenting Cells to improve virotherapy efficacy in Diffuse Midline Gliomas
por: Labiano, Sara, et al.
Publicado: (2022) -
IMMU-09. MODULATING THE MYELOID POPULATION IN DIPG MODELS WITH ONCOLYTIC VIRUS AND COMPLEMENT INHIBITORS SHOWS THERAPEUTIC EFFICACY
por: Puigdelloses, Montserrat, et al.
Publicado: (2021) -
IMMU-08. MICROENVIRONMENT MODULATION BY TIM-3 BLOCKADE IMPROVES THE OUTCOME OF PRECLINICAL DIPG MODELS
por: Ausejo-Mauleon, Iker, et al.
Publicado: (2021) -
THER-01. AWAKING THE IMMUNE SYSTEM WITH AN IMMUNO-ONCOLYTIC VIRUS AS A THERAPEUTIC STRATEGY FOR DIPGs
por: Laspidea, Virginia, et al.
Publicado: (2020)